Catalyst Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CBIO and buy or sell other stocks, ETFs, and their options commission-free!

About CBIO

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). 

CEO
Han Ying, PhD
CEOHan Ying, PhD
Employees
5
Employees5
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1997
Founded1997
Employees
5
Employees5

CBIO Key Statistics

Market cap
672.13M
Market cap672.13M
Price-Earnings ratio
236.95
Price-Earnings ratio236.95
Dividend yield
—
Dividend yield—
Average volume
121.22K
Average volume121.22K
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$19.00
52 Week high$19.00
52 Week low
$6.11
52 Week low$6.11

People also own

Based on the portfolios of people who own CBIO. This list is generated using Robinhood data, and it’s not a recommendation.
Tilray Brands
Ideanomics
SNDL
Nikola
Ocugen, Inc
Zomedica
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.